Lineage plasticity is a hallmark of cancer progression that impacts therapy outcomes, yet the mechanisms mediating this process remain unclear. Here, we introduce a versatile in vivo platform to interrogate neuroendocrine lineage transformation throughout prostate cancer progression. Transplanted mouse prostate...
Transformation to neuroendocrine prostate cancer is often clinically suspected in patients that develop progressive disease, especially visceral metastases, despite a normal or modestly elevated PSA and/or elevated serum markers of neuroendocrine differentiation. Platinum-based chemotherapy is the mainstay of ...
Transformation of castration-resistant prostate cancer (CRPC) into an aggressive neuroendocrine disease (CRPC-NE) represents a major clinical challenge and experimental models are lacking. A CTC-derived eXplant (CDX) and a CDX-derived cell line are established using circulating tumor cells (CTCs) ...
Normally, the DPYSL5 protein regulates the development of neurons in the brain and is not expressed in other parts of the body. However, the researchers now found that antiandrogen treatment caused the DPYSL5 protein to be expressed in prostate cancer cells. As a result, these cells acquired...
prostate cancer cells can lose NE-like features upon return to control, androgen rich conditionsin vitro, indicating NE transdifferentiation is not fixed8,9. However the molecular events involved in this “dedifferentiation” and whether NE-like cells within prostate tumours revert to adenocarcinoma ...
"We thought Ascl1 might be key to the transition, but we needed solid evidence," Dr. Romero says. "With this platform we were able to identify it as essential to the transformation in just three months." Research to develop ASCL1-focused treatment for neuroendocrine prostate cancer ...
These in vitro results further support the concept that prostate cancer cells can tranform in vivo to cells with a NE phenotype and suggest that this transformation might be accelerated in patients by certain therapies for prostate cancer.
Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers. Sci Transl Med. 2023;15(707):eadf7006. Article PubMed PubMed Central CAS Google Scholar George J, Lim JS, Jang SJ, Cun Y, Ozretia L, Kong G, et al. Comprehensive ...
4568 Prostate inflammation might introduce prostate cancer, but might also aggravate the accumulation of genetic insults and transformation of precancerous prostate lesions. Two mouse models were used to study these relations. Neonatal t... A Bergman,T Iwataa,M Vaughn,... - 《Cancer Research》 ...
Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer. NEPC arises de novo only rarely; the disease predominantly develops from adenocarcinoma in response to drug-induced androgen receptor signalling inhibition, although the mechanisms behind this transdifferentiation are a subject of...